Efruxifermin for NASH
Trial Summary
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Efruxifermin for NASH?
Research shows that Efruxifermin, a drug designed to treat non-alcoholic steatohepatitis (NASH), significantly reduced liver fat in patients during clinical trials. In a study, patients receiving Efruxifermin showed a notable decrease in liver fat compared to those who received a placebo, indicating its potential effectiveness for NASH.12345
Is efruxifermin safe for humans?
What makes the drug Efruxifermin unique for treating NASH?
Efruxifermin is unique because it is a fusion protein that combines a part of the human antibody with FGF21, a protein that helps regulate metabolism, and it specifically targets liver fibrosis in NASH, a condition with no approved treatments. Its mechanism involves binding to a specific receptor on cells, which is necessary for its activity, making it different from other treatments that do not use this pathway.478910
What is the purpose of this trial?
This trial is testing a medication called efruxifermin (EFX) to see if it can help people with a specific liver condition called non-cirrhotic NASH/MASH. The patients have significant liver damage but not cirrhosis. EFX aims to improve liver health by reducing swelling and scarring in the liver.
Eligibility Criteria
This trial is for people with a liver condition called non-cirrhotic NASH or MASH, which involves fat buildup and fibrosis (scarring) at stage 2 or 3. Participants should not have cirrhosis, a more advanced liver scarring.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive efruxifermin (EFX) or placebo in a randomized, double-blind, placebo-controlled study
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for event-free survival and other long-term outcomes
Treatment Details
Interventions
- Efruxifermin
Find a Clinic Near You
Who Is Running the Clinical Trial?
Akero Therapeutics, Inc
Lead Sponsor